Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Clin Infect Dis ; 73(12): 2368-2369, 2021 12 16.
Article in English | MEDLINE | ID: covidwho-1597440
2.
Mucosal Immunol ; 15(2): 198-210, 2022 02.
Article in English | MEDLINE | ID: covidwho-1493071

ABSTRACT

As the COVID-19 pandemic is still ongoing, and considering the lack of efficacy of antiviral strategies to this date, and the reactive hyperinflammation leading to tissue lesions and pneumonia, effective treatments targeting the dysregulated immune response are more than ever required. Immunomodulatory and immunosuppressive drugs have been repurposed in severe COVID-19 with contrasting results. The heterogeneity in the timing of treatments administrations could be accountable for these discrepancies. Indeed, many studies included patients at different timepoints of infection, potentially hiding the beneficial effects of a time-adapted intervention. We aim to review the available data on the kinetics of the immune response in beta-coronaviruses infections, from animal models and longitudinal human studies, and propose a four-step model of severe COVID-19 timeline. Then, we discuss the results of the clinical trials of immune interventions with regards to the timing of administration, and finally suggest a time frame in order to delineate the best timepoint for each treatment.


Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , COVID-19/therapy , Immunomodulating Agents/administration & dosage , Immunosuppressive Agents/administration & dosage , Immunotherapy , SARS-CoV-2/drug effects , Animals , Antiviral Agents/adverse effects , COVID-19/diagnosis , COVID-19/immunology , COVID-19/virology , Drug Administration Schedule , Host-Pathogen Interactions , Humans , Immunomodulating Agents/adverse effects , Immunosuppressive Agents/adverse effects , Immunotherapy/adverse effects , SARS-CoV-2/immunology , SARS-CoV-2/pathogenicity , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL